JP2020518633A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518633A5
JP2020518633A5 JP2019560355A JP2019560355A JP2020518633A5 JP 2020518633 A5 JP2020518633 A5 JP 2020518633A5 JP 2019560355 A JP2019560355 A JP 2019560355A JP 2019560355 A JP2019560355 A JP 2019560355A JP 2020518633 A5 JP2020518633 A5 JP 2020518633A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
composition according
modified oligonucleotide
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019560355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518633A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031094 external-priority patent/WO2018204788A1/en
Publication of JP2020518633A publication Critical patent/JP2020518633A/ja
Publication of JP2020518633A5 publication Critical patent/JP2020518633A5/ja
Priority to JP2023023048A priority Critical patent/JP2023075111A/ja
Pending legal-status Critical Current

Links

JP2019560355A 2017-05-04 2018-05-04 アルポート症候群を治療するための方法 Pending JP2020518633A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023023048A JP2023075111A (ja) 2017-05-04 2023-02-17 アルポート症候群を治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501699P 2017-05-04 2017-05-04
US62/501,699 2017-05-04
PCT/US2018/031094 WO2018204788A1 (en) 2017-05-04 2018-05-04 Methods for treatment of alport syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023023048A Division JP2023075111A (ja) 2017-05-04 2023-02-17 アルポート症候群を治療するための方法

Publications (2)

Publication Number Publication Date
JP2020518633A JP2020518633A (ja) 2020-06-25
JP2020518633A5 true JP2020518633A5 (https=) 2021-06-10

Family

ID=62223298

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560355A Pending JP2020518633A (ja) 2017-05-04 2018-05-04 アルポート症候群を治療するための方法
JP2023023048A Pending JP2023075111A (ja) 2017-05-04 2023-02-17 アルポート症候群を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023023048A Pending JP2023075111A (ja) 2017-05-04 2023-02-17 アルポート症候群を治療するための方法

Country Status (13)

Country Link
US (3) US20210100828A1 (https=)
EP (1) EP3618838A1 (https=)
JP (2) JP2020518633A (https=)
KR (1) KR20190141770A (https=)
CN (2) CN110740737A (https=)
AU (1) AU2018261792A1 (https=)
BR (1) BR112019022824A2 (https=)
CA (1) CA3062316A1 (https=)
CL (1) CL2019003153A1 (https=)
MA (1) MA50749A (https=)
MX (1) MX2019013158A (https=)
SG (1) SG11201910099WA (https=)
WO (1) WO2018204788A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076452A1 (en) * 2020-10-05 2022-04-14 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Combination therapy for alport renal disease
CN120731923B (zh) * 2025-09-05 2025-11-04 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) 一种Alport综合征小鼠NMD逃逸模型的构建方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498315B2 (en) * 2004-06-01 2009-03-03 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
NZ601660A (en) * 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US20150031750A1 (en) * 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
PE20142404A1 (es) * 2012-04-25 2015-02-02 Regulus Therapeutics Inc Compuestos de microarn y metodos de modulacion de la actividad de mir-21
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
GB201507926D0 (en) * 2015-05-08 2015-06-24 Proqr Therapeutics N V Improved treatments using oligonucleotides

Similar Documents

Publication Publication Date Title
JP6272880B2 (ja) アルポート症候群の処置方法
Bono et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
JP2015536301A5 (https=)
TWI415605B (zh) 用於預防或治療貓之全身性疾病之血管緊張素ii受體拮抗劑
EP4433025A1 (en) Methods for treating cancer
CN105324395A (zh) 治疗急性肾损伤的方法
JP2022535127A (ja) アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法
JP2025166108A (ja) 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法
JP2018528945A5 (https=)
JP2020518633A5 (https=)
CA2214143A1 (en) Combination compositions containing benazepril or benazeprilat and valsartan
JP2019536803A5 (https=)
JP2023075111A (ja) アルポート症候群を治療するための方法
AU2006278227A1 (en) Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
WO2022232650A1 (en) Methods for reducing agt expression
KR101099189B1 (ko) 당뇨병성 신장병증을 치료하기 위한 피리딜술폰아미도피리미딘
KR20230123921A (ko) 톨-유사 수용체 작용제를 사용한 암 요법
US20250332340A1 (en) Compositions and methods for cns diseases
WO2026076439A1 (en) Compositions and methods for treating pain disorders
US20220324983A1 (en) Use of the anti-p-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease
JP2008222685A (ja) 廃用性骨粗鬆症の予防又は治療剤
JP2008540448A (ja) 糖尿病性腎症の治療において、スロデキシド及び血圧低下薬を用いた併用療法
WO2025050042A1 (en) Therapeutics for cancer with antisense and interferon-gamma